MUC1 peptide vaccination in patients with advanced pancreas or biliary tract cancer.

Kotaro T. Yamamoto, Tomio Ueno, Toru Kawaoka, Shoichi Hazama, Mikiko Fukui, Yutaka Suehiro, Yuichiro Hamanaka, Yoshito Ikematsu, Kohzoh Imai, Masaaki Oka,

PubMed · 2005 · 118 citations · 22 references

Concepts

Abstract

BACKGROUND: To evaluate the immunogenicity of MUC1 peptide vaccine in advanced pancreatic and bile duct cancers, a phase I clinical trial was conducted. MATERIALS AND METHODS: A 100-mer MUC1 peptide consisting of the extracellular tandem repeat domain and incomplete Freund's adjuvant were subcutaneously administered to 6 pancreatic and 3 bile duct cancer patients at weeks 1, 3 and 5 and doses ranging from 300 to 3000 microg. Circulating intracytoplasmic cytokine-positive CD4+ T cells and anti-MUC1 IgG antibodies were measured before and after vaccination. RESULTS: There were no adverse events, except for mild reddening and swelling at the vaccination site. In 8 patients eligible for clinical evaluation, 7 had progressive disease and 1 stable disease with a tendency for increased circulating anti-MUC1 IgG antibody after vaccination. CONCLUSION: This phase I clinical trial revealed the safety of a vaccine containing 100-mer MUC1 peptides and incomplete Freund's adjuvant.

References

22